You are here

BCRF Grantee Since


Area(s) of Focus

Shaomeng Wang, PhD

Warner-Lambert/Parke-Davis Professor in Medicine
Director, Cancer Drug Discovery Program
Professor of Medicine, Pharmacology and Medicinal Chemistry
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan

Current Research

Dr. Wang has led a team of scientists to design and develop a class of completely new anti-cancer drugs that cause breast cancer cells to die by a process called “programmed cell death.” Programmed cell death is a natural process that maintains the health of a tissue by activating signals in old or damaged cells that induce them to commit a type of suicide. Cancer cells learn very early how to ignore death signals so they can continue to multiply and grow. With the support of BCRF, Dr. Wang has advanced two highly potent, targeted anticancer drugs into clinical development for the treatment of advanced breast cancer. His current BCRF funding continues to support the development of combination therapeutic strategies for triple-negative breast cancer and laboratory studies to better understand how these combinations work. His goal is to identify the most effective combinations and rapidly advance them into clinical development for the treatment of triple negative breast cancer.


Dr. Shaomeng Wang's primary research interest is the discovery and development of novel small-molecule therapeutics for the treatment of human breast cancer and other types of cancer focusing on targeting apoptosis and epigenetics pathways. Dr. Wang has built a comprehensive drug discovery program at the University of Michigan and has advanced four novel anticancer drugs into clinical development and several additional compounds into IND-enabling studies. Dr. Wang has published over 250 manuscripts and is an inventor of more than 50 patents and patent applications.